#1
#1 out of 1
health16h ago
Summit Therapeutics presents encouraging Phase II ivonescimab mCRC data; partner's Phase III HARMONi-6 shows OS benefit
- Summit Therapeutics reports encouraging Phase II ivonescimab data in first-line metastatic colorectal cancer.
- 20 mg/kg dose yielded more durable responses with higher DOR in the Phase II study.
- Safety with ivonescimab plus chemotherapy was manageable, with some serious treatment-related AEs.
- Akeso’s HARMONi-6 Phase III in China showed an OS benefit for the combo therapy.
- HARMONi-6 safety remained manageable despite a higher rate of serious AEs with ivonescimab.
- Two studies together highlight potential OS improvements for ivonescimab-containing regimens.
- The report underlines the collaboration between Summit Therapeutics and Akeso.
- The summary notes the information is AI-generated and should be verified with the SEC filings.
- The report references official SEC filings for Summit Therapeutics and the SMMT ticker.
- The article notes the data may have inaccuracies and encourages verification against source documents.
Vote 0